PBLS
Parabilis Medicines, Inc.
29.65
-0.37 (-1.23%)
52w low 22.66
42.49 high
35.2% of range
Financial Analysis
| Ratio | Mar 25 | Jun 25 | Mar 26 | Jun 26 | Trend |
|---|---|---|---|---|---|
| Profitability | |||||
| Operating Margin | -- | -- | -- | -34,382.4% | |
| EBITDA Margin | -- | -- | -- | -34,905.4% | |
| Net Margin | -- | -- | -- | -35,448.0% | |
| FCF Margin | -- | -- | -- | -2,863.5% | |
| Returns | |||||
| Return on Equity | -- | -- | -18.6% | -5.0% | |
| Return on Assets | -- | -- | -11.8% | -4.5% | |
| Return on Inv Capital | -- | -- | 6.3% | -3.9% | |
| Liquidity | |||||
| Current Ratio | -- | -- | 6.12x | 17.91x | |
| Quick Ratio | -- | -- | 6.12x | 17.91x | |
| Cash Ratio | -- | -- | 6.07x | 17.30x | |
| Leverage | |||||
| Debt / Equity | -- | -- | 0.22x | 0.05x | |
| Interest Coverage | -95.06x | -86.90x | -154.19x | -248.82x | |
| Equity Multiplier | -- | -- | 1.57x | 1.12x | |
| Efficiency | |||||
| Asset Turnover | -- | -- | 0.00x | 0.00x | |
| Op CF / Net Income | 0.89x | 0.89x | 1.09x | 0.07x | |
| Investment | |||||
| Capex / Revenue | -- | -- | -- | 416.2% | |
| R&D / Revenue | -- | -- | -- | 26,606.1% | |
| SG&A / Revenue | -- | -- | -- | 7,876.4% | |
Revenue CAGR
--
Net Income CAGR
--
EPS CAGR
--
FCF CAGR
--
Revenue YoY
--